153 related articles for article (PubMed ID: 25746105)
1. HDAC6-Dependent Functions in Tumor Cells: Crossroad with the MAPK Pathways.
Haakenson J; Wu JY; Xiang S; Williams KA; Bai W; Zhang X
Crit Rev Oncog; 2015; 20(1-2):65-81. PubMed ID: 25746105
[TBL] [Abstract][Full Text] [Related]
2. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration.
Williams KA; Zhang M; Xiang S; Hu C; Wu JY; Zhang S; Ryan M; Cox AD; Der CJ; Fang B; Koomen J; Haura E; Bepler G; Nicosia SV; Matthias P; Wang C; Bai W; Zhang X
J Biol Chem; 2013 Nov; 288(46):33156-70. PubMed ID: 24089523
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 6 in health and disease.
Seidel C; Schnekenburger M; Dicato M; Diederich M
Epigenomics; 2015; 7(1):103-18. PubMed ID: 25687470
[TBL] [Abstract][Full Text] [Related]
4. Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.
Lim JA; Juhnn YS
Exp Mol Med; 2016 Jan; 48(1):e204. PubMed ID: 27534532
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
6. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
Kamemura K; Ito A; Shimazu T; Matsuyama A; Maeda S; Yao TP; Horinouchi S; Khochbin S; Yoshida M
Biochem Biophys Res Commun; 2008 Sep; 374(1):84-9. PubMed ID: 18602369
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling Pathway.
Wu H; Cheng XW; Hu L; Takeshita K; Hu C; Du Q; Li X; Zhu E; Huang Z; Yisireyili M; Zhao G; Piao L; Inoue A; Jiang H; Lei Y; Zhang X; Liu S; Dai Q; Kuzuya M; Shi GP; Murohara T
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1549-57. PubMed ID: 27365406
[TBL] [Abstract][Full Text] [Related]
8. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
9. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
10. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Wang Z; Tang F; Hu P; Wang Y; Gong J; Sun S; Xie C
Oncol Rep; 2016 Jul; 36(1):589-97. PubMed ID: 27221381
[TBL] [Abstract][Full Text] [Related]
11. HDAC6: physiological function and its selective inhibitors for cancer treatment.
Yang PH; Zhang L; Zhang YJ; Zhang J; Xu WF
Drug Discov Ther; 2013 Dec; 7(6):233-42. PubMed ID: 24423654
[TBL] [Abstract][Full Text] [Related]
12. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
Lee YS; Lim KH; Guo X; Kawaguchi Y; Gao Y; Barrientos T; Ordentlich P; Wang XF; Counter CM; Yao TP
Cancer Res; 2008 Sep; 68(18):7561-9. PubMed ID: 18794144
[TBL] [Abstract][Full Text] [Related]
13. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
14. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
15. HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1.
Moses N; Zhang M; Wu JY; Hu C; Xiang S; Geng X; Chen Y; Bai W; Zhang YW; Bepler G; Zhang XM
Cells; 2020 Oct; 9(10):. PubMed ID: 33020410
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances.
Qu M; Zhang H; Cheng P; Wubshet AK; Yin X; Wang X; Sun Y
Front Immunol; 2023; 14():1216548. PubMed ID: 37638049
[TBL] [Abstract][Full Text] [Related]
17. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
18. [Histone deacetylase 6: structure, functions and development of selective inhibitors].
Liu RS; Fang H
Yao Xue Xue Bao; 2015 Jan; 50(1):7-14. PubMed ID: 25924468
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Tsuji G; Okiyama N; Villarroel VA; Katz SI
J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
[TBL] [Abstract][Full Text] [Related]
20. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
